Liquidia Corp

LQDA remains in a clear Stage 2 advance with persistent higher highs and lows beneath rising EMAs. The recent shallow pullback found support at the 9/21 EMAs, offering a favorable continuation entry. Momentum remains intact with EMAs stacked and rising, and RS strength supports further upside. We recommend buying now on shallow pullbacks into the rising short-term EMAs for continuation participation.

• ↑Q1 2026 net product sales reached $129.9 M, up 44% QoQ
• ↑Utrepia market share expanded from 10% to 23% shortly after launch
• ↓Negative earnings yield and weak book-to-price indicate valuation concerns